Fibroblast in Cutaneous Leishmaniasis
- Conditions
- Cutaneous Leishmaniasis.Cutaneous leishmaniasisB55.1
- Registration Number
- IRCT20150715023218N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Ages 15-65
Scar lesions caused by Cutaneous leishmaniasis grade 3 to 7;
The willingness to provide informed consent for participation in the trial and the ability to communicate with the investigator during follow ups.
Use of Retinoids in the last 6 months
Pregnancy
Laser therapy in the last 6 months
Cancer or any chronic systemic disease
Chemical therapy
Mesotherapy
Active infection to Leishmaniasis in the scar
Oragan or cell transplantation
Autoimmune disease
Breast feeding
Dermal Filler in the last 6 months
Plastic surgery at the site of Cutaneous leishmaniasis lesion
Use of Corticosteroids
Excessive exposure to sun.
Subjects who are enrolled in any other clinical trial using systemic medication; or any other treatment that might interfere with this study
Subjects with evidence of infection on area to be treated or elsewhere on body.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dermal thickness. Timepoint: Before intervention, 2, 6 and 12 months after the third transplantation of Fibroblasts. Method of measurement: Sonography.;Elasticity. Timepoint: Before intervention, 2, 6 and 12 months after the third transplantation of Fibroblasts. Method of measurement: Cotometer.;Wound Diameter. Timepoint: Before intervention, 2, 6 and 12 months after the third transplantation of Fibroblasts. Method of measurement: visioFace.
- Secondary Outcome Measures
Name Time Method Patients Satisfaction. Timepoint: Before intervention, 2, 6 and 12 months after the third transplantation of Fibroblasts. Method of measurement: Questionnaire.